Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Recurrence × elotuzumab × Clear all

Phase

Status

Active not recruiting 3 Recruiting 2 Completed 2 Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 7 Recurrence 1

Interventions

Dexamethasone 8 venetoclax 4 Rituximab 4 selinexor 3 pembrolizumab 3 ibrutinib 3 Lenalidomide 3 Gemcitabine 3 Drug Therapy 3 Cytarabine 3 Bendamustine Hydrochloride 3 gilteritinib 2 fludarabine phosphate 2 carfilzomib 2 Tablets 2 Surveys and Questionnaires 2 Oxaliplatin 2 Etoposide 2 Cetuximab 2 Calcium Dobesilate 2 Busulfan 2 Bortezomib 2 Azacitidine 2 vistusertib 1 urelumab 1 tucotuzumab celmoleukin 1 trametinib 1 tocilizumab 1 tisagenlecleucel 1 thymoglobulin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05170789 2022-05-04

ESdRRMM

Tulane University

Phase 2 Withdrawn

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡